INCE the first kidney transplant in the mid-fifties, the replacement of faulty organs is no longer an experimental technique, but a life-saving procedure for thousands of patients every year. However, the routine implementation of transplantation as a reparative therapy faces two major hurdles: First, the recipient must endure a lifelong immunosuppression regime in order to prevent graft rejection. The chronic administration of cyclosporine and other immunosuppressants is commonly associated with severe side effects such as life-threatening infections, hepatic toxicity, renal failure and cancer. Second, the current availability of organs and tissues for transplantation is markedly insufficient to satisfy the demand. There are more than 78,000 patients currently waiting for transplantation in the United States. However, only 5984 cadaveric donors were recovered in 2000. 1 Although this situation could be ameliorated with the development of more efficient worldwide organ sharing programmes, alternative sources are clearly necessary. Advances in bioengineering, for instance, have led to the development of artificial organs (heart) and structural tissues (bone, cartilage). However, these strategies would be impractical for the replacement of tissues involved in more complex physiological functions. Interspecific transplantation (xenotransplantation) would have a broader range of applications, but the immunological barriers between species have proven insurmountable thus far. In addition, the risk of transmission of zoonoses to the recipient may compromise the overall safety of this approach.
The concept of stem cell technologies has been coined in recent years to describe a most promising alternative to conventional donor-dependent transplantation. This novel field is the result of the unlikely confluence of disciplines such as immunology, cellular biology, embryology, and transplantation surgery. It focuses on the study of stem cells, a vague label used to describe cells from various origins and functions that, to different extents, share two common properties: The ability of self-renewing in an undifferentiated state and the capacity to adopt many terminal fates. If harnessed, these unique properties of stem cells could be used to generate organs and tissues for transplantation from an unlimited supply of self-renewable cells.
Despite the sense of novelty that surrounds this emerging field, the notion of stem cells has been in use for several decades. It was originally introduced to describe elusive populations of bone marrow cells that appear to act as perpetual repositories of blood cells during the lifetime of the individual. Transplantation of these stem cells can repopulate the hematopoietic system of recipients whose bone marrow has been destroyed by high-dose chemotherapy or radiation therapy. The widespread use of bone marrow transplantation to treat leukaemia is proof that stem cell therapies are no longer a theoretical speculation, but a powerful medical tool that has been used successfully for many years.
However, the concept of pluripotent stem cells was not introduced until the initial establishment of mouse embryonic stem (ES) cells.
2, 3 It was first used to define cultured cells from the inner cell mass (ICM) of the early blastocyst (e3.5). The ICM gives rise to the three embryonal layers of the embryo proper (endoderm, ectoderm and mesoderm), while the surrounding trophectoderm only develops into extraembryonic tissue. It is important to stress that ES cells are an in vitro artifact because the ICM from where these cells are isolated is only a transient developmental stage. Cultured ICM cells are artificially frozen in this stage, which allows their indefinite proliferation in an undifferentiated status.
The pluripotency of these cells was demonstrated by their extensive differentiation potential in vitro, as well as their ability to form teratocarcinomas upon injection in immunodeficient recipients 2,3 and to take part in the generation of chimaeric animals when aggregated to morulae or injected into blastocysts. 4 The observation that donor ES cells are able to colonise the germ line of recipient embryos suggested a direct route for transgenesis and established the basis for gene targeting technologies. The availability of large populations of these immortal cells made it feasible to target specific genes, despite the low frequency of homologous recombination in mammalian cells. Targeted clones can be easily selected in vitro and used to generate chimaeric mice by blastocyst microinjection. Mice with donorderived gametes are backcrossed into the original back-ground of the ES cells, which yields an ideal 50% of targeted offspring (for review, see 4). Using this technology, several hundred mutant mouse lines have been generated since gene targeting in ES cells was first reported. 5, 6 Most of these targeting experiments have been designed to inactivate genes (knockout), thus enabling the study of their function and regulation.
For more than a decade, the major challenge of stem cell biologists was to isolate ES cells from other species, with the idea of targeting specific genes in large animals. This technology could then be used to create large animal models for human genetic diseases, increase livestock output or improve the production of therapeutic proteins from transgenic animals. 7, 8 Unexpectedly, most attempts were unsuccessful. Although ES-like cells could be isolated with relative ease from many species, their self-renewal ability rarely matched that of mouse ES cells, and germline transmission was never proven. Further efforts to establish ES cell lines from livestock were seemingly abandoned with the development of nuclear transfer technologies, 9,10 which soon afterwards enabled the generation of genetically modified animals in one single step, following gene targeting of somatic cells in vitro.
11 It is somewhat surprising that the potential use of ES cells for therapeutic purposes was not scientifically acknowledged up to this point. The techniques involved in the establishment of monkey 12 and human 13 ES cells are essentially the same used for mouse ES cell isolation, and yet this effort was not actively pursued until the mid-nineties. Pluripotent embryonic germ (EG) cells were also established at this time, using procedures equally comparable to those used for mouse EG cell isolation. 14 Human ES and EG cell lines share many of the properties of their mouse counterparts, including unlimited proliferative potential, telomerase activity, and the ability to generate embryoid bodies in vitro. Human ES cells also show Oct-4 expression, contribute to chimaeras and form teratomas when injected into SCID mice. 15, 16 Addition of different combinations of factors to the culture medium results in the activation of discrete specialisation pathways, as shown by the appearance of markers for virtually every tissue of therapeutic value. 16 Taken together, these observations suggest that human ES cells are a most powerful tool for the ex vivo generation of tissues for transplantation. However, human ES cell research has been highly controversial since its inception, due to the ethical implications of the way these cells are obtained. This, and a sudden explosion of reports about the extraordinary plasticity of many adult stem cells, has shed new light not only on the way this research is perceived by society, but also on old dogmas about the regenerative potential of many tissues.
Aside from the field of haematopoiesis, the concept of adult stem cells is relatively new. It describes populations of relatively undifferentiated cells found in most adult tissues, where they seem to function as natural reservoirs in response to tissue damage or ageing. This imprecise definition engulfs tissue progenitors (already committed to cell types of any given tissue) and common progenitors of tissues derived from the same embryonal layer. At least theoretically, we could say that different stem cells run along a gradient of regressive undifferentiation, at the end of which we would place ES cells.
Adult stem cells are elusive in vivo, and finding their biological niches is still a major challenge for developmental biologists. Thus far, we have only been able to study
17 Similarly, adult rodent neural crest cells and multipotent bone marrow cell lines contribute to tissues from the three germ layers upon injection into early mouse and chick embryos. 18, 19 Induced transdifferentiation has also been observed after bone marrow transplantation in FAH Ϫ/Ϫ mice. 20 These mutant mice are models of fatal hereditary type I tyrosinemia, characterised by progressive liver failure in humans. Upon transplantation, bone marrow cells rehome into the liver and differentiate into functional hepatocytes, rescuing the mutant phenotype.
In summary, stem cells in culture might give us only a deceptive reflection of their real nature and functions in vivo. Perhaps all stem cells are fundamentally similar in terms of their regenerative potential, and it is only their in vivo or in vitro microenvironment what appears to restrict them to specific fates. It is tempting to think that all stem cell families found in different tissues would be local vestiges of undifferentiated cells that persist beyond embryonic development. If this hypothesis proved to be true, any non-terminally differentiated cell would have the potential of reverting to an ES-like status given the appropriate conditions. In fact, nuclear transfer experiments have established beyond doubt that even terminally specialised cells can be dedifferentiated to a totipotent stage. These findings add up to the notion that cell commitment and differentiation are not absolute determinants, and that diverse inductive microenvironments will effectively shape the potential of most stem cell types.
Regardless of their origin, multipotent stem cell lines are now widely available to the scientific community. Many technical obstacles, however, stand in the way to the routine application of stem cell technologies in reparative medicine. For instance, current in vitro settings can hardly mimic the exquisite biochemical regulation that governs development and differentiation in vivo. Most of these mechanisms are still relatively unknown; therefore, researchers often fail to obtain fully functional or sufficiently enriched tissues from stem cells in culture. Even if we could eventually generate large amounts of highly purified tissue for transplantation, we still would have to address fundamental issues such as the recurrence of autoimmune processes, the possible tumourigenic potential of stem cell-derived tissues and how to induce long-term tolerance.
Among the many diseases and conditions that could eventually be treated with stem cell therapies, type I diabetes is perhaps the most obvious target. This disease is the result of an autoimmune response against pancreatic beta cells, which results in islet destruction and subsequent deregulation of the levels of sugar in the blood. Chronic administration of insulin is a life-saving treatment, but it cannot ensure the maintenance of steady normoglycaemia and is commonly associated to the long-term incidence of complications such as blindness, amputations, and renal failure. It is encouraging that one successful form of cell therapy (islet transplantation) has already been in use for more than a decade to treat-and effectively cure-the disease. In recent years, this field has benefited greatly from the development and clinical implementation of a steroidfree protocol for long-term induction of tolerance. 21 However, the current shortage of islets for transplantation has limited the widespread implementation of this therapy. For this reason, many groups have focused on the common objective of inducing islet neogenesis from stem cells in vitro. The recent report that human ES cell-derived embryoid bodies spontaneously give rise to insulin-producing cells 22 was not surprising, but it established proof of principle that ES cells have the potential to become beta-like cells in vitro. Still, embryoid bodies comprise tissues derived from all three embryonic layers, and insulin-producing cells only represent a very modest percentage of these structures. To enrich ES cell-derived cultures for insulin-producing cells, a genetic engineering strategy based on the selective ablation of insulin-negative cells in vitro has been recently proposed. 23 In this approach, mouse ES cells are stably transfected with a gene that confers resistance to the drug G418 placed under the control of the insulin promoter. When these cells are allowed to spontaneously differentiate in the presence of G418, only those that naturally express insulin are selected. Insulin-producing cells obtained in this way were able to revert diabetes upon implantation in mice rendered diabetic by streptozotocin treatment. However, there are reasonable doubts about the nature of the selected colonies. Not all insulin-producing cells are real beta cells, as shown by the presence of insulin staining in many adult tissues unrelated to the pancreas. 24, 25 The same critique must be extended to a highly publicised report where a slight variation on a protocol normally used to differentiate neural cells from ES cells resulted on the generation of pseudoislets in vitro. 26 A significant percentage of the cells present in these structures unequivocally express insulin, as shown by immunohistochemistry and RT-PCR. However, the intracellular concentration of insulin was only 1/50 of the typical values observed in beta cells, and they did not correct hyperglycaemia when implanted in streptozotocin-treated mice. This is not unexpected, considering that these cells do not express the transcription factor IpfI/pdx1, which is essential for the maintenance of the beta cell phenotype. 27 It is a well-known fact that the development of the central nervous system and the endocrine pancreas share many transcription factors, 28, 29 which may explain the presence of insulin-expressing cells in the brain and following a neural-oriented differentiation protocol. However, since these two systems derive from distinct embryonal layers, insulin-producing cells of ectodermal origin must be fundamentally different from genuine endodermal beta cells.
In our opinion, a thorough understanding of the molecular events that determine the natural evolution of the pancreas is key to successfully induce undifferentiated cells to become functional beta cells. In other words, the best approach to induce neogenesis of islets in vitro would be to recapitulate their embryonic development. Although there is still a long way to fully unravel this complex process, we already know a few critical steps in the initiation of the pancreatic programme. At day e8.5 of mouse embryonic development, the pancreas consists of two evaginations (dorsal and ventral) from the gut epithelium. The budding of these rudiments has been triggered by a localised downregulation of shh and upregulation of the master pancreatic gene IpfI/pdx1. 27,29 Notch signalling appears to control the choice between endocrine and exocrine fates, through a process denominated lateral specification. 28, 30 This highly conserved mechanism results in the generation of scattered endocrine cells from an initially homogeneous field of undifferentiated progenitors. Lack of notch signalling results in high intracellular levels of the proendocrine transcription factor ngn3, whereas, cells with active notch signalling remain as undifferentiated progenitor cells. A transient burst of ngn3 expression enables the differentiation of proendocrine cells into all four types of pancreatic endocrine cells (alpha, beta, gamma, and PP). The adoption of each endocrine fate occurs preferentially at specific time points during pancreatic development. This observation suggests that ngn3-positive cells respond differentially to an evolving milieu of signals (Fig. 1) . The identification of all these signalling pathways will be critical in order to design in vitro protocols for bona fide islet neogenesis, regardless of the type of stem cell used as raw material.
An alternative to the establishment of fully functional islets in vitro would be to characterise immature precursors that would become functional islets upon transplantation into an appropriate in vivo microenvironment. The promise of this approach has been suggested by numerous experiments where neural uncommitted precursors differentiate according to the region where they are implanted. 31, 32 Once again, the barriers of stem cell plasticity may not be absolute, which might be used to our advantage in order to design simpler therapeutic approaches.
In summary, it is legitimate to be optimistic about technologies that may harness the natural regenerative potential of our own tissues. However, the reason why such potential seems to be somehow downregulated in our species remains to be determined. For instance, if cells in the bone marrow can experimentally rescue a faulty liver in the mouse, 21 why is this mechanism not normally active in humans? Is there any relation between some types of cancer and the persistence of undifferentiated cells in adult life? We are just starting to comprehend some of the basic principles that govern stem cell biology, and perhaps it would be precipitated to rush into clinical applications before these principles are sufficiently understood. 
Ngn3
Ϫ cells remain as undifferentiated progenitors and may later become p48 ϩ exocrine progenitors. Proendocrine cells differentiate into alpha cells around day 9; beta cells around e12; and somatostatin-producing cells as from e15.5. The identity of the signals that determine the fate of proendocrine cells at specific time points of development remains to be elucidated. In a first phase, IpfI/pdx1 is expressed in the region of the gut epithelium that will become pancreas. Around e10.5, the expression of this gene is downregulated in the buds, but reappears again in differentiated beta cells (adapted from ref.
27
).
STEM CELLS AND THEIR CLINICAL APPLICATION

